RU2015143206A - Композиции и их применение для лечения осложнений аневризматического субарахноидального кровоизлияния - Google Patents
Композиции и их применение для лечения осложнений аневризматического субарахноидального кровоизлияния Download PDFInfo
- Publication number
- RU2015143206A RU2015143206A RU2015143206A RU2015143206A RU2015143206A RU 2015143206 A RU2015143206 A RU 2015143206A RU 2015143206 A RU2015143206 A RU 2015143206A RU 2015143206 A RU2015143206 A RU 2015143206A RU 2015143206 A RU2015143206 A RU 2015143206A
- Authority
- RU
- Russia
- Prior art keywords
- therapeutic agent
- application
- pharmaceutically acceptable
- delayed
- acceptable carrier
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 16
- 208000032843 Hemorrhage Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 claims 45
- 238000000034 method Methods 0.000 claims 44
- 229940124597 therapeutic agent Drugs 0.000 claims 44
- 239000003937 drug carrier Substances 0.000 claims 24
- 230000003111 delayed effect Effects 0.000 claims 22
- 210000001627 cerebral artery Anatomy 0.000 claims 17
- 239000002245 particle Substances 0.000 claims 14
- 230000001225 therapeutic effect Effects 0.000 claims 14
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 13
- 239000012530 fluid Substances 0.000 claims 12
- 206010008118 cerebral infarction Diseases 0.000 claims 10
- 239000011859 microparticle Substances 0.000 claims 10
- 239000002105 nanoparticle Substances 0.000 claims 10
- 238000002347 injection Methods 0.000 claims 9
- 239000007924 injection Substances 0.000 claims 9
- 201000006474 Brain Ischemia Diseases 0.000 claims 8
- 108090000312 Calcium Channels Proteins 0.000 claims 8
- 102000003922 Calcium Channels Human genes 0.000 claims 8
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 8
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229940125400 channel inhibitor Drugs 0.000 claims 7
- 239000011159 matrix material Substances 0.000 claims 6
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 5
- 238000013268 sustained release Methods 0.000 claims 5
- 239000012730 sustained-release form Substances 0.000 claims 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 4
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 4
- 229940125968 Voltage-Gated Calcium Channel inhibitor Drugs 0.000 claims 4
- 229920002988 biodegradable polymer Polymers 0.000 claims 4
- 239000004621 biodegradable polymer Substances 0.000 claims 4
- 239000000480 calcium channel blocker Substances 0.000 claims 4
- 230000002490 cerebral effect Effects 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- 229920002674 hyaluronan Polymers 0.000 claims 4
- 229960003160 hyaluronic acid Drugs 0.000 claims 4
- 238000007913 intrathecal administration Methods 0.000 claims 4
- 238000007914 intraventricular administration Methods 0.000 claims 4
- 229960000715 nimodipine Drugs 0.000 claims 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 4
- 210000002330 subarachnoid space Anatomy 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 3
- 210000001367 artery Anatomy 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 claims 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 claims 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 2
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 claims 2
- XTFPDGZNWTZCMF-DHZHZOJOSA-N 3-o-methyl 5-o-[(e)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 XTFPDGZNWTZCMF-DHZHZOJOSA-N 0.000 claims 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims 2
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 claims 2
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 claims 2
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 claims 2
- 206010010071 Coma Diseases 0.000 claims 2
- WTOVRSWDBLIFHU-UHFFFAOYSA-N Lemildipine Chemical compound COC(=O)C1=C(C)NC(COC(N)=O)=C(C(=O)OC(C)C)C1C1=CC=CC(Cl)=C1Cl WTOVRSWDBLIFHU-UHFFFAOYSA-N 0.000 claims 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims 2
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 2
- 229960000528 amlodipine Drugs 0.000 claims 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 2
- 210000002551 anterior cerebral artery Anatomy 0.000 claims 2
- 229950007556 aranidipine Drugs 0.000 claims 2
- 229950004646 azelnidipine Drugs 0.000 claims 2
- -1 bamidipine Chemical compound 0.000 claims 2
- 229960004916 benidipine Drugs 0.000 claims 2
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 claims 2
- 230000002051 biphasic effect Effects 0.000 claims 2
- 230000006931 brain damage Effects 0.000 claims 2
- 231100000874 brain damage Toxicity 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 210000001715 carotid artery Anatomy 0.000 claims 2
- 210000004004 carotid artery internal Anatomy 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 229960003020 cilnidipine Drugs 0.000 claims 2
- 230000001054 cortical effect Effects 0.000 claims 2
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 238000009826 distribution Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229950003102 efonidipine Drugs 0.000 claims 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 2
- 229960003580 felodipine Drugs 0.000 claims 2
- 210000004055 fourth ventricle Anatomy 0.000 claims 2
- 238000007917 intracranial administration Methods 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 229960004427 isradipine Drugs 0.000 claims 2
- 229960004340 lacidipine Drugs 0.000 claims 2
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 claims 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 2
- 210000003140 lateral ventricle Anatomy 0.000 claims 2
- 229950001530 lemildipine Drugs 0.000 claims 2
- 229960004294 lercanidipine Drugs 0.000 claims 2
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 claims 2
- 229960003963 manidipine Drugs 0.000 claims 2
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 claims 2
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims 2
- 210000003657 middle cerebral artery Anatomy 0.000 claims 2
- 229960001783 nicardipine Drugs 0.000 claims 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 2
- 229960001597 nifedipine Drugs 0.000 claims 2
- 229960005366 nilvadipine Drugs 0.000 claims 2
- 229960000227 nisoldipine Drugs 0.000 claims 2
- 229960005425 nitrendipine Drugs 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229950004891 pranidipine Drugs 0.000 claims 2
- 238000001179 sorption measurement Methods 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 230000001839 systemic circulation Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 210000000211 third ventricle Anatomy 0.000 claims 2
- 230000001052 transient effect Effects 0.000 claims 2
- 238000009827 uniform distribution Methods 0.000 claims 2
- 210000002385 vertebral artery Anatomy 0.000 claims 2
- 108091006146 Channels Proteins 0.000 claims 1
- 102100032950 GPI mannosyltransferase 1 Human genes 0.000 claims 1
- 101000730688 Homo sapiens GPI mannosyltransferase 1 Proteins 0.000 claims 1
- 210000004289 cerebral ventricle Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940076372 protein antagonist Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/793,767 US10092524B2 (en) | 2008-06-11 | 2013-03-11 | Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage |
| US13/793,767 | 2013-03-11 | ||
| PCT/US2014/023748 WO2014164904A1 (en) | 2013-03-11 | 2014-03-11 | Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015143206A true RU2015143206A (ru) | 2017-04-18 |
Family
ID=49157870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015143206A RU2015143206A (ru) | 2013-03-11 | 2014-03-11 | Композиции и их применение для лечения осложнений аневризматического субарахноидального кровоизлияния |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10092524B2 (enExample) |
| EP (1) | EP2968166A4 (enExample) |
| JP (1) | JP2016512527A (enExample) |
| KR (1) | KR101902319B1 (enExample) |
| CN (1) | CN105324108A (enExample) |
| AU (1) | AU2014248877A1 (enExample) |
| BR (1) | BR112015022218A2 (enExample) |
| CA (1) | CA2905327A1 (enExample) |
| GB (1) | GB2528801A (enExample) |
| HK (1) | HK1216002A1 (enExample) |
| NZ (1) | NZ629730A (enExample) |
| RU (1) | RU2015143206A (enExample) |
| SG (1) | SG11201507398XA (enExample) |
| WO (1) | WO2014164904A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10092524B2 (en) | 2008-06-11 | 2018-10-09 | Edge Therapeutics, Inc. | Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage |
| EP2694133B1 (en) | 2011-04-05 | 2018-05-23 | Edge Therapeutics, Inc. | Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow |
| GB2556500A (en) * | 2015-05-29 | 2018-05-30 | Edge Therapeutics Inc | Compositions and methods for reducing visual loss |
| US20190054022A1 (en) * | 2016-04-07 | 2019-02-21 | Edge Therapeutics, Inc. | Formulations of site-specific, microparticulate compositions and their use to improve outcome after aneursymal subarachnoid hemorrhage |
| CN108403629B (zh) * | 2018-04-26 | 2019-11-05 | 徐州医科大学 | 一种尼莫地平口服长效悬浮液及其制备方法 |
| WO2020227558A2 (en) * | 2019-05-07 | 2020-11-12 | Yale University | Maximizing distribution and minimizing washout of injectates in bone and method for enhanced aspirate extraction |
| WO2020235947A1 (ko) * | 2019-05-22 | 2020-11-26 | 경북대학교 산학협력단 | Cacb1 유래 펩타이드, Cacb1 유래 펩타이드의 변이체 및 이의 용도 |
| WO2021168351A1 (en) * | 2020-02-20 | 2021-08-26 | Postsurgical Therapeutics, Inc. | Brain drug delivery system and method |
| WO2021262725A1 (en) * | 2020-06-22 | 2021-12-30 | Curelator, Inc. | Systems and methods for segmentation of a user population based on time-based variations in biomarker levels |
| US11452690B1 (en) | 2021-01-27 | 2022-09-27 | ECI Pharmaceuticals, LLC | Oral liquid compositions comprising amlodipine besylate and methods of using the same |
| WO2022185235A1 (en) * | 2021-03-03 | 2022-09-09 | Crannmed Limited | Alginate based particles as a temporary embolic agent |
| WO2025151741A1 (en) * | 2024-01-10 | 2025-07-17 | Brown David Donaldson | Methods of treating migraine headache or tension headache with hyaluronic acid |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
| US5527893A (en) | 1987-09-18 | 1996-06-18 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
| US4937270A (en) | 1987-09-18 | 1990-06-26 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
| DE69024953T3 (de) | 1989-05-04 | 2005-01-27 | Southern Research Institute, Birmingham | Einkapselungsverfahren |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| JPH09507487A (ja) | 1994-01-05 | 1997-07-29 | アーキュール，インコーポレーテッド | 選ばれた性質を有するアミンイミドおよびオキサゾロンをベースとした分子の系統的モジュール製造 |
| US5712171A (en) | 1995-01-20 | 1998-01-27 | Arqule, Inc. | Method of generating a plurality of chemical compounds in a spatially arranged array |
| US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
| US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
| AT404429B (de) | 1995-06-09 | 1998-11-25 | Immuno Ag | Anti-plasma-antikörper-präparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| ATE314843T1 (de) | 1996-03-12 | 2006-02-15 | Pg Txl Co Lp | Wasserlösliche paclitaxel-prodrogen |
| DK0949905T3 (da) | 1996-12-20 | 2001-10-22 | Alza Corp | Injicertbart depotelpræparat og fremgangsmåde til fremstilling |
| CA2296056A1 (en) | 1997-07-10 | 1999-01-21 | Keith Baker | Methods for universally distributing therapeutic agents to the brain |
| AU9596698A (en) | 1997-10-15 | 1999-05-03 | Thomas Jefferson University | Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
| JP2000070366A (ja) | 1998-09-02 | 2000-03-07 | Arute:Kk | 容器兼用注射器及び容器兼用注射器への凍結乾燥製剤の封入方法 |
| US20050214227A1 (en) * | 1999-03-08 | 2005-09-29 | Powderject Research Limited | Microparticle formulations for sustained-release of bioactive compounds |
| US7651703B2 (en) | 1999-10-15 | 2010-01-26 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
| US6284283B1 (en) | 1999-10-21 | 2001-09-04 | Alkermes Controlled Therapeutics, Inc. | Method of producing sub-micron particles of biologically active agents and uses thereof |
| WO2001047571A2 (en) | 1999-12-29 | 2001-07-05 | Regeneration Technologies, Inc. | System for reconstituting pastes and methods of using same |
| CA2396628A1 (en) | 2000-01-25 | 2001-08-02 | Edwards Lifesciences Corporation | Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| JP2002003406A (ja) | 2000-06-21 | 2002-01-09 | Sankyo Co Ltd | 脳血管攣縮予防製剤 |
| US20030032676A1 (en) | 2001-08-09 | 2003-02-13 | Kimelberg Harold K. | Drugs for treatment of cerebral injury and methods of use thereof |
| WO2003020208A2 (en) | 2001-08-31 | 2003-03-13 | Neuron Therapeutics, Inc. | Treatment of neurologic hemorrhage |
| US20040235801A1 (en) | 2001-10-25 | 2004-11-25 | Jean-Pierre Julien | Therapy for stroke |
| DE60236686D1 (de) | 2001-11-22 | 2010-07-22 | Dainippon Sumitomo Pharma Co | Nichtmenschliches tiermodell, das nicht auf eine immunopotenzierende synthetische verbindung anspricht |
| EP1478406B1 (en) | 2002-02-27 | 2011-01-05 | PharmaIN Corporation | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
| TW200307011A (en) | 2002-04-18 | 2003-12-01 | Chugai Pharmaceutical Co Ltd | Hyaluronic acid modifier |
| DK1499719T3 (da) | 2002-04-30 | 2011-02-28 | Bayer Healthcare Llc | Faktor VII- eller VIIa-polypeptidvarianter |
| CN103638040A (zh) | 2002-07-03 | 2014-03-19 | 派瑞克科学公司 | 透明质酸组合物以及使用方法 |
| US7713551B2 (en) | 2002-09-11 | 2010-05-11 | Elan Pharma International Ltd. | Gel stabilized nanoparticulate active agent compositions |
| JP4092994B2 (ja) | 2002-09-13 | 2008-05-28 | ニプロ株式会社 | プレフィルドシリンジキット |
| CA2547531C (en) | 2002-11-26 | 2013-11-12 | Seacoast Neuroscience, Inc. | Buoyant polymer particles for delivery of therapeutic agents to the central nervous system |
| US20070207211A1 (en) | 2003-04-10 | 2007-09-06 | Pr Pharmaceuticals, Inc. | Emulsion-based microparticles and methods for the production thereof |
| ES2427092T3 (es) | 2003-04-10 | 2013-10-28 | Evonik Corporation | Un método para la producción de micropartículas a base de emulsión |
| EP2444069B1 (en) | 2003-07-23 | 2019-06-05 | Evonik Corporation | Controlled release compositions |
| WO2005020933A2 (en) * | 2003-09-02 | 2005-03-10 | University Of South Florida | Nanoparticles for drug-delivery |
| ES2522575T3 (es) | 2003-10-22 | 2014-11-17 | Encelle, Inc. | Composiciones de hidrogel bioactivo para la regeneración del tejido conjuntivo |
| US20080124400A1 (en) | 2004-06-24 | 2008-05-29 | Angiotech International Ag | Microparticles With High Loadings Of A Bioactive Agent |
| US20060205733A1 (en) | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| US8034762B2 (en) | 2004-09-02 | 2011-10-11 | Cognosci, Inc. | Treatment of subarachnoid hemorrhage with Apo E analogs |
| US7829527B2 (en) | 2005-02-02 | 2010-11-09 | University Of Vermont And State Agricultural College | Emergence of a R-type Ca2+ channel (Cav 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage |
| EP2500031A3 (en) | 2005-02-24 | 2012-12-26 | Joslin Diabetes Center, Inc. | Compositions and Methods for Treating Vascular Permeability |
| US20060217340A1 (en) | 2005-03-23 | 2006-09-28 | University Of Vermont And State Agricultural College | Methods and products for treating hypertension by modulation of TRPC3 channel activity |
| US20080188400A1 (en) | 2005-04-26 | 2008-08-07 | Maxygen Holdings Ltd. | Methods For Treating Bleeding |
| EP1906993A2 (en) | 2005-07-15 | 2008-04-09 | Novo Nordisk Health Care AG | USE OF FACTOR VIIa OR FACTOR VIIa EQUIVALENTS FOR PREVENTING OR ATTENUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) IN PATIENTS TREATED WITH ANTIPLATELET THERAPY |
| GB0515492D0 (en) | 2005-07-28 | 2005-08-31 | Reckitt Benckiser Healthcare | Improvements in or relating to compositions,articles and methods |
| CA2625862A1 (en) | 2005-10-14 | 2007-04-26 | Transform Pharmaceuticals, Inc. | Liquid pharmaceutical compositions of nimodipine |
| AU2006318447A1 (en) | 2005-11-21 | 2007-05-31 | The Board Of Trustees Of The University Of Alabama For And On Behalf Of The University Of Alabama | Methods of using small molecule compounds for neuroprotection |
| WO2008087424A1 (en) | 2007-01-18 | 2008-07-24 | Reckitt Benckiser N.V. | Dosage element and a method of manufacturing a dosage element |
| CA2685225A1 (en) | 2007-04-25 | 2008-11-06 | Musculoskeletal Transplant Foundation | Reinforced biological mesh for surgical reinforcement |
| US9005183B2 (en) | 2007-05-16 | 2015-04-14 | Health Knight, Llc | System and method for treating erectile dysfunction |
| KR101554250B1 (ko) | 2007-06-11 | 2015-09-18 | 알. 로치 맥도날드 | 뇌혈관 연축의 예방을 위한 약물 전달 시스템 |
| US10092524B2 (en) | 2008-06-11 | 2018-10-09 | Edge Therapeutics, Inc. | Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage |
| ES2718612T3 (es) | 2007-12-20 | 2019-07-03 | Evonik Corp | Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual |
| US20100008968A1 (en) | 2008-06-26 | 2010-01-14 | Lampe John W | Method for treating cardiovascular diseases using rho kinase inhibitor compounds |
| MX344359B (es) | 2008-08-22 | 2016-12-14 | Reckitt Benckiser Healthcare (Uk) Ltd | Composición particulada ingerible para el dolor de garganta. |
| EP2331082B1 (en) | 2008-09-11 | 2021-01-06 | Evonik Corporation | Solvent extraction microencapsulation with tunable extraction rates |
| CA2737484C (en) | 2008-09-18 | 2017-10-10 | Surmodics Pharmaceuticals, Inc. | Microencapsulation process with solvent and salt |
| WO2010085608A1 (en) | 2009-01-23 | 2010-07-29 | Surmodics Pharmaceuticals, Inc. | Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same |
| US20130059008A1 (en) | 2009-01-23 | 2013-03-07 | Jeffrey L. Atkinson | Drying methods for tuning microparticle properties |
| CA2750003A1 (en) | 2009-01-23 | 2010-07-29 | Surmodics Pharmaceuticals, Inc. | Controlled release systems from polymer blends |
| US20100291027A1 (en) | 2009-05-14 | 2010-11-18 | Jason Campbell | Hyaluronic acid (ha) injection vehicle |
| US20110033463A1 (en) | 2009-08-06 | 2011-02-10 | Medtronic, Inc. | Apheresis, administration of agent, or combination thereof |
| RU2562263C9 (ru) | 2009-12-22 | 2016-04-27 | Евоник Корпорейшн | Способ и рабочий узел для приготовления микрочастиц с использованием эмульсии |
| CN102834104A (zh) | 2010-02-22 | 2012-12-19 | 优势医疗公司 | 治疗脑的出血性病状的方法和组合物 |
| CN107260684A (zh) | 2010-03-29 | 2017-10-20 | 赢创有限公司 | 用于在局部给药位点改进药物组合物的滞留的组合物和方法 |
| CN107115270A (zh) | 2011-02-11 | 2017-09-01 | 优势医疗公司 | 用于改善患有蛛网膜下腔出血的人的预后的组合物和方法 |
| EP2694133B1 (en) | 2011-04-05 | 2018-05-23 | Edge Therapeutics, Inc. | Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow |
| US9399019B2 (en) * | 2012-05-09 | 2016-07-26 | Evonik Corporation | Polymorph compositions, methods of making, and uses thereof |
-
2013
- 2013-03-11 US US13/793,767 patent/US10092524B2/en not_active Expired - Fee Related
-
2014
- 2014-03-11 CA CA2905327A patent/CA2905327A1/en not_active Abandoned
- 2014-03-11 GB GB1516997.2A patent/GB2528801A/en not_active Withdrawn
- 2014-03-11 EP EP14780318.3A patent/EP2968166A4/en not_active Withdrawn
- 2014-03-11 RU RU2015143206A patent/RU2015143206A/ru not_active Application Discontinuation
- 2014-03-11 AU AU2014248877A patent/AU2014248877A1/en not_active Abandoned
- 2014-03-11 WO PCT/US2014/023748 patent/WO2014164904A1/en not_active Ceased
- 2014-03-11 BR BR112015022218A patent/BR112015022218A2/pt not_active IP Right Cessation
- 2014-03-11 SG SG11201507398XA patent/SG11201507398XA/en unknown
- 2014-03-11 KR KR1020157028454A patent/KR101902319B1/ko not_active Expired - Fee Related
- 2014-03-11 NZ NZ629730A patent/NZ629730A/en not_active IP Right Cessation
- 2014-03-11 HK HK16103935.4A patent/HK1216002A1/zh unknown
- 2014-03-11 CN CN201480026815.5A patent/CN105324108A/zh active Pending
- 2014-03-11 JP JP2016501330A patent/JP2016512527A/ja active Pending
-
2016
- 2016-05-16 US US15/156,152 patent/US20160324796A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015022218A2 (pt) | 2017-07-18 |
| CA2905327A1 (en) | 2014-10-09 |
| AU2014248877A1 (en) | 2015-10-01 |
| NZ629730A (en) | 2017-03-31 |
| HK1216002A1 (zh) | 2016-10-07 |
| JP2016512527A (ja) | 2016-04-28 |
| AU2014248877A8 (en) | 2015-10-29 |
| KR20150136084A (ko) | 2015-12-04 |
| KR101902319B1 (ko) | 2018-09-28 |
| US20130243864A1 (en) | 2013-09-19 |
| GB2528801A (en) | 2016-02-03 |
| EP2968166A4 (en) | 2016-10-05 |
| US20160324796A1 (en) | 2016-11-10 |
| WO2014164904A1 (en) | 2014-10-09 |
| CN105324108A (zh) | 2016-02-10 |
| SG11201507398XA (en) | 2015-10-29 |
| EP2968166A1 (en) | 2016-01-20 |
| US10092524B2 (en) | 2018-10-09 |
| GB201516997D0 (en) | 2015-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015143206A (ru) | Композиции и их применение для лечения осложнений аневризматического субарахноидального кровоизлияния | |
| JP2016512527A5 (enExample) | ||
| Wang et al. | Facile nose-to-brain delivery of rotigotine-loaded polymer micelles thermosensitive hydrogels: In vitro characterization and in vivo behavior study | |
| JP5882993B2 (ja) | 抗精神病薬デポ型注射用組成物 | |
| EP2394663B1 (en) | Compositions for injectable in-situ biodegradable implants | |
| JP2019059752A (ja) | 関節痛の治療のためのコルチコステロイド | |
| Rein et al. | Meloxicam-loaded solvent exchange-induced in situ forming beta-cyclodextrin gel and microparticle for periodontal pocket delivery | |
| JP2014515744A5 (enExample) | ||
| JP6695140B2 (ja) | 水性カプサイシノイド配合物ならびにその製造法および使用法 | |
| KR100517210B1 (ko) | 통증,염증및경련억제용관주용액 | |
| CA2974208A1 (en) | Composition and methods to improve stability, dosing, pharmacodynamics and product shelf life of endocannabinoids, phytocannabinoids and synthetic cannabinoids delivered by nasal inhaler | |
| RU2016144847A (ru) | Система интравентрикулярной доставки лекарственного средства для улучшения исхода после повреждения головного мозга, нарушающего мозговое кровообращение | |
| TW201442713A (zh) | 醫藥配方 | |
| Phadke et al. | A recent update on drug delivery systems for pain management | |
| KR20160094952A (ko) | 수계 캡사이시노이드 제형 및 제조방법 및 용도 | |
| JP6749962B2 (ja) | 網脈絡膜障害の抑制剤 | |
| Tiwari et al. | A review on use of novel drug delivery systems in herbal medicines | |
| Taraballi et al. | Potential avoidance of adverse analgesic effects using a biologically “smart” hydrogel capable of controlled bupivacaine release | |
| WO2014153384A1 (en) | Corticosteroid formulations for the treatment of joint pain and methods of use thereof | |
| WO2019094625A1 (en) | Methods and compositions for parenteral administration of cannabidiol in the treatment of convulsive disorders | |
| CN103405385A (zh) | 一种替莫唑胺静脉注射脂肪乳及其制备方法 | |
| JP6247720B2 (ja) | 関節痛の治療のためのコルチコステロイド | |
| AU2012214137B2 (en) | Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage | |
| JP2014509318A5 (enExample) | ||
| WO2025054397A1 (en) | Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180821 |